Benefits and adverse effects of endocrine therapy

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Colleoni, M ^a   Giobbie Hurder, A ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adjuvant treatment; Early breast cancer; Endocrine therapy; Side effects

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GOSERELIN; LETROZOLE; LEUPRORELIN; METHOTREXATE; PLACEBO; TAMOXIFEN; TAMOXIFEN CITRATE;

ADJUVANT THERAPY; ARTHRALGIA; BONE DENSITY; BREAST CANCER; BREAST SURGERY; CANCER CLASSIFICATION; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FRACTURE; GENE OVEREXPRESSION; HEART INFARCTION; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; INDIVIDUALIZATION; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; MENOPAUSAL SYNDROME; MENSTRUAL IRREGULARITY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYALGIA; OVARIECTOMY; OVARY CANCER; OVARY CYST; OVARY FUNCTION; OVERALL SURVIVAL; PATIENT ATTITUDE; PATIENT SELECTION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TUMOR VASCULARIZATION; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS;

EID: 78649377987     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq281     Document Type: Conference Paper

References (41)

1. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
2. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
3. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
4. Colleoni M, Rotmensz N, Peruzzotti G et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol 2007; 18: 1632-1640.
5. Schoppmann SF, Bayer G, Aumayr K et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004; 240: 306-312.
6. Ross JS, Fletcher JA, Linette GP et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307-325.
7. Viale G, Giobbie-Hurder A, Regan MM et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine responsive breast cancer. Results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26: 5569-5575.
8. Colleoni M, Rotmensz N, Robertson C et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 2002; 13: 273-279.
9. Goldhirsch A, Gelber RD, Yothers G et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 2001; 30: 44-51.
10. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348: 1189-1196.
11. Ravdin RG, Lewison EF, Slack NH et al. Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet 1970; 131: 1055-1064.
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 2005; 365: 1687-1717.
13. Kafmann M, Jonat W, Kleeberg U et al. Goserelin, a depot gonadotrophinreleasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 1989; 7: 1113-1119.
14. Schmid P, Untch M, Kossé V et al. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol 2007; 25: 2509-2515.
15. International Breast Cancer Study Group (IBCSG). Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003; 95: 1833-1846.
16. Jonat W, Kaufmann M, Sauerbrei W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002; 20: 4628-4635.
17. Berglund G, Nystedt M, Bolund C et al. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized trial. J Clin Oncol 2001; 19: 2788-2796.
18. Analysis at Eight Years by 'Nolvadex' Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer Br J Cancer 1988; 57: 608-611.
19. Fisher B, Costantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479-484.
20. Breast Cancer Trials Committee, Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987; 330: 171-175.
21. Stewart HJ, Prescott RJ, Forrest APM. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93: 456-462.
22. Baum M. Has tamoxifen had its day? Breast Cancer Res 2002; 4: 213-217.
23. Braithwaite RS, Chlebowski RT, Lau J et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003; 18: 937-947.
24. Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol 2003; 30: 763-775.
25. Love RR, Wiebe DA, Feyzi JM et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994; 86: 1534-1539.
26. Love RR, Newcomb PA, Wiebe DA et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990; 82: 1327-1332.
27. Klijn JG, Blamey RW, Boccardo F et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001; 19: 343-353.
28. de la Rochefordiere A, Asselain B, Campana F et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993; 341: 1039-1043.
29. Aebi S, Gelber S, Castiglione-Gertsch M et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000; 355: 1869-1874.
30. Love RR, Van Dinh N, Quy TT et al. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. J Clin Oncol 2008; 26: 253-257.
31. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348: 2431-2442.
32. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
33. The BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009; 361: 766-776.
34. Coombes RC, Hall E, Gibson LJ et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
35. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462.
36. Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509-518.
37. Sehdev S, Martin G, Sideris L et al. Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. Curr Oncol 2009; 16: s14-s23.
38. Paganini-Hill A, Clark JL. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000; 64: 175-176.
39. Schilder CM, Seynaeve C, Beex LV et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2010; 28: 1294-1300.
40. Ribi KE, Phillips KA, Sun Z. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. J Clin Oncol 2009; 27(15 Suppl): abstract 510.
41. Fallowfield L. Acceptance of adjuvant therapy and quality of life issues. Breast 2005; 14: 612-616.